CD8A and type 1 diabetes mellitus: Following teplizumab (anti-CD3) and alefacept (LFA-3_Ig fusion protein) treatment, subjects with a greater proportion of exhausted islet specific CD8+ T cells demonstrated slower progression of T1D (75, 76).